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Abstract 
 
Alzheimer’s disease (AD) is the most common cause of dementia. The symptoms of AD mainly 
include short-term memory loss, cognitive defects, and poor judgment, consequently leading to death. 
Currently 28 million people worldwide are suffering from AD; however, a cure for the disease to 
retard its initiation and progression has not been developed. Indeed, the discovery of the drug has 
been very challenging due to involvement of multiple pathogenic factors in the pathogenesis of AD. 
For example, the aggregates of amyloidogenic amyloid- (A) peptides are accumulated in the AD-
affected brain. Among the aggregates, soluble and structured A oligomers have been suggested to be 
toxic to nerve cells. Additionally, highly concentrated metal ions [e.g., Cu(I/II), Zn(II), Fe(II/III)] are 
found in senile plaques, composed of A aggregates. Disrupted homeostasis of these metal ions would 
affect neuron signaling, apoptosis, and inflammation. Lastly, reactive oxygen species (ROS) can be 
overproduced through Fenton-like reactions causing oxidative damage to nucleic acids and cellular 
organelles. The studies presented in this thesis describe the development of chemical tools able to 
regulate single or multiple pathogenic component(s). In Chapter 1, an introduction of the hypotheses 
of AD is described, along with previously reported chemical tools designed to target pathological 
elements. In Chapter 2, our interdisciplinary studies of new small molecules towards distinct 
pathological factors, rationally designed via a novel structure-property-directed design strategy, are 
summarized. Lastly, in Chapter 3, a series of fluorescent sensors for metal ions in living cells, is 
illustrated, which could provide a better understanding of a link of their concentration and 
compartmentalization to the pathogenesis of AD. Overall, our approaches and findings presented 
herein would be useful for constructing effective chemical tools and therapeutics for AD, ultimately 
serving the illumination of complex pathogenesis of the disease in the future. 
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Chapter 1. 
 
Development of Chemical Tools Targeting Pathogenic Factors of Alzheimer’s Disease 
 to Elucidate its Complex Pathogenesis of the Disease 
 
 


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1.1. Introduction 
Alzheimer’s disease (AD) is the most common neurodegenerative disease, estimated approximately 
60-80% of dementia.1 The disease was first reported in 1906;1 however, the etiology of the disease has 
not still been clear.2-4 The main symptoms of the disease include loss of episodic memory, cognitive 
decline, disorientation, and poor judgment, which could ultimately lead to death.1,5 The hallmarks of 
AD consist of senile plaques and neurofibrillary tangles, mostly composed of amyloid- (A) 
aggregates and hyperphosphorylated tau (ptau) protein, respectively.5-8 The Alzheimer’s Association 
reported that the resultant social cost per patient for health care and long-term care services hovers at 
approximately 50 million won annually.1 Although 28 million people worldwide are currently suffered 
by the disease, a few medications (e.g., donepezil, memantine, galantamine, and rivastigmine), 
approved by the U.S. Food and Drug Administration (FDA), are available but they provide only 
temporary symptom relief by blocking a single risk factor, cholinesterase or N-methyl-D-aspartate 
(NMDA) receptor.1,3 Until now, due to the complexity of AD pathology, a cure for the disease has not 
been successfully developed. In this Chapter, we illustrate the representative pathological factors of 
AD and their inter-relationships. In addition, some previously reported chemical tools able to target 
and modulate such elements are presented. 
 
1.2. Hypotheses of AD 
1.2.1. Amyloid Cascade Hypothesis 
 
 
 
Figure 1.1. Production and aggregation of A peptides. A is generated by the proteolytic cleavage of 
APP via - and -secretases. The Amonomers (A40 or A42) are prone to aggregate into oligomers, 
protofibrils, and fibrils. 
 
In order to invent an effective treatment for AD, the etiology of the disease needs to be first identified. 
Multiple risk factors of AD have been suggested through several hypotheses: the amyloid cascade 
hypothesis, metal ion hypothesis, and the oxidative stress hypothesis.2-5,9,10 Amyloid hypothesis claims 
that the aggregation of misfolded A proteins is relevant to the neurotoxicity in AD.2,4,5,10 A peptides 
are generated via the proteolytic cleavage of amyloid precursor protein (APP) by - and -
secretases.5,11 The isoforms of A peptides are determined depending on the cleavage site of -
secretase.5,11 A40 and A42 are the dominant products from the cleavage reactions with the difference 
in two hydrophobic amino acid residues (i.e., isoleucine and alanine) in the C-terminus.4,5,11 A 
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monomers are natively disordered; however, external factors, such as pH and temperature, cause 
peptides to be partially folded,11 which tend to spontaneously aggregate into oligomers, protofibrils, 
and fibrils (Figure 1.1).2,3,5-7 Among various species, structured soluble A oligomers are recently 
reported to be the most toxic species which could disrupt cellular signaling pathways by interfering 
membrane receptors [e.g., -amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptor and 
NMDA receptor] or forming annular structures inserted in the membrane.8,11  
 
1.2.2. Metal Ion Hypothesis 
Homeostasis of transition metal ions, including Cu(I/II) and Zn(II), are impaired in the AD-affected 
brain.4,5,12-14 Since metal ions are responsible for numerous signal transduction pathways including 
apoptosis, inflammation, and cell proliferation, dysregulated metal ions are also pathogenic.4 In 
general, the concentrations of intracellular Cu(I/II) and Zn(II) are tightly regulated by various metal 
transporters (e.g., ATP7A and ATP7B for copper;4,15 ZnT3 for zinc4,16). Under pathological conditions, 
however, such metal ions are not properly compartmentalized in the regions of the brain (e.g., 
hippocampus, cortex, amygdala, and putamen).4 For example, the deficiency and overload of Cu(I/II) 
are simultaneously observed in the hippocampus and putamen of AD patients.17,18 The loss of protein-
bound metal ions in metalloenzymes [e.g., cytochrome c oxidase and Cu/Zn-superoxide dismutase 
(SOD)] can influence neuron degeneration and apoptosis.5 In addition to the effects of metal ions on 
the activities of metalloenzymes, they can form 1:1 complexes with the peptide [Kd = 10-11 to 10-8 M 
for Cu(II); Kd = 10-9 to 10-6 M for Zn(II)], which facilitates A aggregation and stabilizes toxic 
oligomeric species.4,13,14,19 The exact mechanisms of how metal ions could affect the aggregation 
pathways of A have not been identified.13  
 
1.2.3. Oxidative Stress Hypothesis 
The overproduction of reactive oxygen species (ROS) can trigger damage to the nucleic acid, 
membranes, and cellular organelles, consequently leading to neuronal death.5,12,20 The oxidative stress 
hypothesis proposes that the sources of ROS could be hypoxia and amyloid-related events.5,21 First, 
the condition of hypoxia stimulates the respiratory system in mitochondria, reducing dioxygen (O2) to 
superoxide (O2•–), that prompts oxidative stress through overexpression of hypoxia-inducible factors 
(HIFs).22 Under hypoxia conditions, however, HIFs cannot be degraded;23 thus, the oxidative damages 
are further amplified through positive feedback.  
In addition, as described above, dysregulated metal ions can bind to A, generating metal–A 
complexes (vide supra). Particularly, redox-active Cu(II)–A could generate hydrogen peroxide 
(H2O2) through the H2O2 cycle (Figure 1.2)5,7,9,24 upon reduction from Cu(II) to Cu(I), with a half 
potential as 0.34 V [versus normal hydrogen electrode (NHE)].25 Moreover, in the presence of 
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reducing agents, such as ascorbic acids or glutathione,7,25 Cu(I)–A additionally cleaves the O–O 
bond of H2O2 to generate hydroxyl radicals (•OH) through Fenton-like reactions (Figure 1.2).5,7,9,24 
ROS-mediated oxidative stress can be controlled via mitochondrial detoxifying mechanisms (i.e., 
SOD and catalase) under normal conditions;2 however, abnormal mitochondria in the AD-affected 
brain are able to overproduce O2•– and release H2O2 into the cytoplasm.2,5  
 
 
 
Figure 1.2. Proposed mechanisms of Cu(I/II)–A-mediated ROS production. Redox properties of 
Cu(I/II)–A can direct the generation of H2O2 and •OH through the H2O2 cycle and Fenton cycle, 
respectively. 
 
1.3. Development of Chemical Tools to Elucidate the Pathogeneses of AD  
1.3.1. A-targeting Agents 
In order to identify the role of A aggregation in the neurotoxicity,2,4,5,10 chemical tools capable of 
targeting and regulating them would be necessary. For example, thioflavin-T (ThT) and Pittsburgh 
compound B (PIB) derivatives have been utilized to interact with -sheet-enriched amyloid 
aggregates in vivo (Figure 1.3.a).2,4 In addition, some A antibodies (e.g., bapineuzumab, 
solanezumab, ponezumab) are undergoing Phase III clinical trials, which can specifically bind to 
certain A sequences and lower the levels of A in the brain of AD patients.27 Moreover, the 
inhibitors against -secretase, composed of at least four proteins [i.e., presenilin, nicastrin, anterior 
pharynx (APH1), and presenilin enhancer 2 (PEN2)], were developed to completely prevent the 
generation of A peptides.3,28,29 Unfortunately, -secretase has other substrates (e.g., notch receptor 1) 
rather than APP; thus, suppression of this secretase could cause notch-related lethal side effects.29,30 
As an alternative approach, small molecules able to modulate A aggregation into off-pathway have 
been developed.29,31 For instance, -sheet breakers have been recently proposed to inhibit or disrupt 
the formation of -sheet by binding to the self-recognition site of A species (Figure 1.3.b).29,31 In an 
inverse direction, Wanker and coworkers have reported the molecule, O4, that could interact with 
hydrophobic residues of A and accelerates A fibrillization leading to reduction of the amount of 
toxic oligomers (Figure 1.3.b).32  
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Figure 1.3. A-targeting agents and metal chelators. (a and b) Structures of A-targeting and their 
reaction mechanisms towards A aggregations. (c) Structures of metal chelators. 
 
1.3.2. Metal Chelators  
In order to redistribute abnormally compartmentalized metal ions in the AD-affected brain, effective 
metal chelators possessing reasonable binding affinities towards Cu(II), Zn(II), and Fe(II/III) are 
necessary. At the same time, metal binding affinities of chemical tools should be adjusted to avoid 
stripping out the essential biometals in metalloproteins.8 Moreover, since metal ions have been known 
to directly bind A species as well as overproduce ROS, chemical reagents able to attenuate the 
interactions between metal ions and the peptide would be valuable.4,8 Clioquinol (CQ) is the common 
example of metal chelators utilized as an AD therapeutics (specifically, chelation of Cu(II) and Zn(II) 
[Kd = 10-10 M for Cu(II); 10-8 M for Zn(II)] as well as decrease in the level of Ain the brain of AD 
patients (Figure 1.3.c).3,33,34 Due to the toxicity of impurity (i.e., 5,7-diiodoquinolin-8-ol) generated 
during mass production, however, further clinical trials were halted. As a derivative of CQ, PBT2 was 
shown to function same as CQ, along with greater blood-brain barrier (BBB) permeability (Figure 
1.3.c).3,34,35 Moreover, both CQ and PBT2 are shown to reorganize the disturbed homeostasis of metal 
ions and activate metalloenzymes responsible for A clearance (i.e., MMP-2 and MMP-3).3,35  
 
1.3.3. Multifunctional Chemical Tools 
Given that various risk factors found in AD are intertwined with one another (vide supra), the 
development of multifunctional chemical tools towards several elements (i.e., A, metal ions, metal–
A, and ROS) has recently received significant attention. Cyc-KLVFF, one of the cyclen derivatives 
incorporated to the amino acid residues in the self-recognition site of A, has shown its novel ability 
to chelate Cu(II) and break the -sheets as designed as a dual-functional chemical tool (Figure 1.4).36 
Interestingly, this molecule could further decrease H2O2 production mediated by Cu(II)–A42.36 As 
described in the previous section, the dyshomeostasis of redox-active metal ions is closely correlated 
with overproduction of ROS;5,7,9,24 thus, Cyc-KLVFF can function as an antioxidant by preventing the 
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oxidative damages induced by ROS.36 Additionally, our group has reported the molecule, ML, 
composed of rationally chosen structural moieties responsible for interacting with metal-free A, 
metal-bound A, and metal ions as well as scavenging free radicals (Figure 1.4).10 The framework of 
ML is based on p-I-stilbene37 and L2-b,38 each of which is a well-known A imaging agent and a 
previously reported small molecule targeting metal–A, respectively. In order to afford a tetradentate 
ligand with a relatively high metal binding affinity,39 an additional hydroxyl group was incorporated 
into the framework. The distorted square planar geometry of the Cu(II)–ML complex is indicated, 
which is not favorable for the geometry of Cu(I)–ML and thus subsequently prevents ROS generation 
via Fenton-like reactions.5,7,9,24 Moreover, it contains the moieties of quinoline and phenol that are 
previously reported to scavenge free radicals.10 ML could redirect the aggregation pathways of both 
metal-free A and metal–A as well as regulate the levels of ROS (i.e., inhibition of forming ROS 
and scavenging of the free radicals). In addition to the rationally designed molecules, natural products 
have been investigated to function as multifunctional tools. For example, melatonin, a hormone 
responsible for maintaining the circadian rhythm, is a well-known antioxidant.40 The amide functional 
group of melatonin could contribute to the interaction with Cu(II) and Zn(II),40 inhibiting the 
formation of metal–A oligomers (Figure 1.4).41 Vitamine E (-tocopherol) was observed to inhibit 
A aggregation as well as disaggregate preformed A fibrils along with its antioxidant capacity 
(Figure 1.4).42 
 
 
 
Figure 1.4. Examples of multifunctional chemical tools towards A, metal ions, and ROS. The 
structural moieties for A interaction (highlighted in green), metal binding (highlighted in yellow), 
and radical scavenging (highlighted in blue) arer responsible for their activity towards pathogenic 
elements. 
  
1.4. Conclusions 
A growing number of AD patients is emerging as a severe social problem; however, the clear 
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medication has not been provided. Multiple pathological factors, including A, metal ions, and ROS, 
are found in the AD-affected brain. These pathogenic factors are observed to be closely inter-related 
with one another, aggravating the neurotoxicity. In order to advance our understanding of the 
complicated pathology of AD and provide a new insight into the discovery of therapeutics, the 
development of chemical tools towards modulation of such pathological components would be 
necessary. In this Chapter, we illustrate some examples of chemical reagents, including A-targeting 
agents, metal chelators, and multifunctional chemical tools. 
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Chapter 2. 
 
Tuning Structures and Properties for Developing Novel Chemical Tools  
towards Distinct Pathogenic Elements in Alzheimer’s Disease 
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2.1 Introduction 
Various pathological factors [e.g., amyloid- (A), metal ions, metal-bound A (metal–A), reactive 
oxygen species (ROS)] are reported to be involved in the pathogenesis of Alzheimer’s disease (AD).1-
10 A peptides, produced via the proteolytic cleavage of amyloid precursor protein (APP), tend to 
aggregate into oligomers, protofibrils, and fibrils.1,2,8-10 Recently, soluble A oligomers are suggested 
to be major toxic species that cause neuronal atrophy and death.2,10-13 Additionally, highly 
concentrated metals (e.g., copper, zinc, iron) found in senile plaques are observed to directly interact 
with A generating metal–A complexes, which can facilitate A aggregation and stabilize toxic A 
oligomers.8,13-15 Moreover, complexes of A and redox-active metal ions, including Cu(I/II), are 
presented to overproduce ROS via Fenton-like reactions leading to damage of nucleic acids, lipids, 
and cellular organelles.2,16-18 Due to the complex link among multiple pathological elements to AD 
pathology, however, a cure for the disease has not been still discovered.8,19  
In order to gain a better understanding of the pathogenesis of AD, chemical tools capable of 
targeting and modulating pathogenic factors have been devised.20-39 A variety of anti-amyloidogenic 
compounds that interact with metal-free A species and mediate peptide aggregation have been 
constructed.20-22 Small molecules, exhibited to specifically modify the aggregation of metal–A over 
metal-free A, have also been invented.23-25 In addition, several antioxidants have been shown as 
chemical tools against ROS-induced oxidative stress.26,27 Moreover, given that the individual elements 
have been detected to be intertwined with each other in the AD-affected brain, the design of small 
molecules as multifunctional tools for regulating the inter-connections among AD pathogenic 
components has currently received attention.28-39 For example, some small molecules, including (E)-5-
(4-hydroxystyryl)quinolone-8-ol (10c),32 N,N-dimethyl-p-phenylenediamine (DMPD),37 and N1-((1H-
pyrrol-2-yl)methyl)-N4,N4-dimethylbenzene-1,4-diamine (4),39 were shown to alter the aggregation of 
metal-free A and metal–A as well as quench free radicals. Taken together, the efforts on 
engineering chemical tools able to target and control single or multiple pathogenic components(s) and 
control their activities have been made to provide molecular-level insights into the pathology of AD. 
The development of such tools, however, has been challenging. 
Herein, we report new small molecules (1–3; Figure 2.1) that distinguishably interact and react 
with the pathological targets found in AD (i.e., metal-free A, metal–A, and free radicals). Our 
compounds, 1–3, were designed via a rational structure-property-directed strategy. As depicted in 
Figure 2.1, through an extremely minor structural variation [i.e., change of only one nitrogen (N) or 
sulfur (S) donor atom in the backbone], we are able to tune the properties of compounds (e.g., 
oxidation potentials, interactions with metal-free and metal-bound A) and subsequently afford 
reactivities against disparate pathological features. Overall, our studies demonstrate that small 
molecules as chemical tools for modulating distinct pathological components of AD can be rationally 
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constructed through a structure-property-based design strategy. Such design tactics would be further 
applied for devising chemical reagents utilized for other neurodegenerative disorders. 
 
 
 
Figure 2.1. Rational design of the small molecules (1–3) able to have distinct properties and 
reactivities with pathological factors found in AD. (a,b) Structures of DMA and the bidentate ligands 
used for construction of 1–3. (c) Structural variations of 1–3, obtained via a change of only one N or S 
donor atom in the framework, and the difference in their oxidation and targets. 
 
2.2 Results and Discussion 
2.2.1. Structure-Property-Directed Principle for Designing Chemical Tools Able to Target 
Distinct Pathological Components of AD 
To design the backbone of the new compounds (1–3), we rationally selected two structural moieties, 
i.e., DMA and bidentate ligands composed of N and S donor atoms (Figure 2.1a,b). The conjugation 
of two structural groups could achieve different redox properties of small molecules and their 
distinguishable interactions with metal ions, metal-free A, metal–A, and free radicals. First, DMA 
(Figure 2.1a) is a structural portion employed for previously reported chemical tools targeting metal-
free A and/or metal–A.34,37,40,41 In addition, the DMA-containing structures [e.g., DMPD,37 439], 
incorporated with one N donor atom at the para position of the N,N-dimethyl group, are known to 
undergo one- or two-electron oxidation.37,39,42,43 Such oxidation is indicated to direct the capabilities of 
compounds against regulation of metal-free A, metal–A, and free radicals.37,39,44 Second, in order to 
interact with metal ions [i.e., Cu(II), Zn(II)] as well as metal ions bound to A, the bidentate ligands 
containing N and S donor atoms were introduced into the framework of 1–3 (Figure 2.1b).45,46 Lastly, 
to tune the extent of compounds’ oxidation, 1–3 were obtained through the modification of only one N 
or S donor atom (Figure 2.1c). The oxidation potentials of small molecules have been previously 
demonstrated to be critical for interactions and reactivities with pathological targets, including metal-
free A, metal–A, and free radicals.39,44 As summarized in Figure 2.1c, our new molecules (1–3), 
developed via a very slight structural variation, are observed to have the differences in their oxidation 
and coverage of pathological targets for interactions and reactivities (vide infra). 
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2.2.2. Synthesis and Characterization of 1–3 
As described in Scheme 2.1, new small molecules (1–3) were prepared. Compound 1 was afforded by 
ring opening of ethylene sulfide with DMPD. Compounds 2 and 3 were obtained through copper-
catalyzed C–S bond formation between 4-iodo-aniline and the corresponding alkanethiols, followed 
by conversion of terminal groups into thiol (for 2) or amino (for 3) functionality. Synthesis of 1–3 was 
confirmed by spectroscopic and spectrometric methods (Figures 2.2-2.4). Moreover, our molecules 
were verified to interact with Cu(II) and Zn(II) (Figure 2.5) as we designed. Furthermore, 1–3 are 
suggested to be blood-brain barrier (BBB) permeable based on the calculated and experimentally 
obtained values (logBB > −1.0 and −logPe < 5.4; Table 2.1). 
 
Scheme 2.1. Synthetic routes to 1–3. 
 
 
 
 
 
 
Figure 2.2. 1H (a, 400 MHz) and 13C (b, 100 MHz) NMR spectra of 1 in CD2Cl2. 
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Figure 2.3. 1H (a, 400 MHz) and 13C (b, 100 MHz) NMR spectra of 2 in CD2Cl2. 
 
 
 
 
Figure 2.4. 1H (a, 400 MHz) and 13C (b, 100 MHz) NMR spectra of 3 in CD3OD. 
 
 
 
 
Figure 2.5. Metal binding of 1–3 observed by UV–Vis. Spectral changes of our molecules are 
monitored upon titration of various concentrations of (a) Cu(II) and (b) Zn(II). Conditions: 
[compound] = 50 M, [CuCl2 or Zn(NO3)2] = 0 (blue), 25, 50, 100, and 250 M (orange), EtOH [for 
Cu(II) binding studies] or buffered solution [20 M HEPES, pH 7.4, 150 M NaCl, for Zn(II) binding 
studies], room temperature, incubation for 10 min.  
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Table 2.1. Values (MW, clogP, HBA, HBD, PSA, logBB, and –logPe) of 1–3.  
 
 
 
aMW, molecular weight, bclogP, calculated log of water-octanol partition coefficient, cHBA, hydrogen 
bond acceptor atoms, dHBD, hydrogen bond donor atoms, ePSA, polar surface area, flogBB = 0.152 ൈ 
clogP − 0.0148 ൈ PSA ൅ 0.139, g−logPe, the values obtained using the parallel artificial membrane 
permeability assay adapted for the BBB (PAMPA–BBB) were calculated by the PAMPA Explorer 
software v. 3.5. Compounds assigned to be CNS are able to penetrate the BBB and thus be available 
in the central nervous system (CNS), compounds assigned to be CNS– compounds have poor BBB 
permeability and thus their availability in the CNS are considered minimal. 
 
 
2.2.3. Redox Properties of 1–3 
To determine whether a minor structural variation of compounds could lead to distinguishable 
compounds’ oxidation potentials as we designed (Figure 2.1), their redox properties were investigated 
by cyclic voltammetry (CV) and UV–visible spectroscopy (UV–Vis). The oxidation potentials of each 
compound were measured by CV (Figures 2.6 and 2.7). The lower value of the anodic peak potential 
(Epa) indicates that the compound is relatively easy to be oxidized.47 The Epa value of 1 containing a 
moiety of DMPD is ca. 0.22 V [versus Ag/Ag(I)], significantly lower than those of 2 and 3 (Epa = ca. 
0.54/0.80 and 0.75 V, respectively) composed of a 4-(dimethylamino)-benzenethiol (BT) group 
(Figure 2.6 and Table 2.2). Although the Epa values of 2 and BT could not be measured in H2O due to 
their limited solubility, 1 has a much lower Epa value than 3 in H2O, similar to the observation in 
DMSO (Figure 2.7 and Table 2.3). Based on the Epa values of DMPD and BT (ca. 0.23 and 0.93 V, 
respectively), the structural portion of DMPD would be mainly responsible for the lower Epa value of 
1. 
1 2 3 Lipinski’s rules and others 
MWa 196 213 196 ≤ 450 
clogPb 2.16 3.22 1.91 ≤ 5.0 
HBAc 2 1 2 ≤ 10 
HBDd 1 0 2 ≤ 5 
PSA (Å2)e 15.3 3.24 29.3 ≤ 90 
logBBf 0.232 0.580 –0.0130 < –1.0 (poorly) 
–logPeg 
 4.59 ± 0.02 
(CNS+) 
 4.52 ± 0.07 
(CNS+) 
4.45 ± 0.01 
(CNS+) 
–logPe < 5.4 (CNS+) 
–logPe > 5.7 (CNS–) 
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Figure 2.6. Redox potentials of 1–3 measured in DMSO. The oxidation of (a) 1–3 and (b) their 
structural portions was monitored by cyclic voltammetry. The Epa values at 250 mV/s are summarized 
in (c). Conditions: [compound] = 1 mM; 0.1 M tetra-N-butylammonium perchlorate (in DMSO); 
various scan rates [25 (red), 50, 100, 150, 200, and 250 mV/s (blue)]; room temperature; three 
electrodes composed of the glassy carbon working electrode, platinum counter electrode, and 
Ag/Ag(I) reference electrode. 
 
 
Table 2.2. Quantitative data of cyclic voltammograms of 1–3 in DMSO. 
 
Scan rate 
(mV/s) 
1  2 
Epa (V) Epa (V)  Epa (V) ipa (A)  Epa (V) ipa (A) 
25 0.186 0.186  0.520 1.25  0.750 6.67 
50 0.196 0.196  0.522 2.39  0.756 9.69 
100 0.208 0.208  0.532 2.82  0.779 12.2 
150 0.214 0.214  0.534 3.66  0.784 14.4 
200 0.219 0.219  0.538 4.40  0.796 15.1 
250 0.220 0.220  0.538 4.41  0.802 17.5 
Scan rate 
(mV/s) 
3  DMPD  BT 
Epa,1 (V) ipa,1 (A)  Epa,2 (V) ipa,2 (A)  Epa (V) ipa (A) 
25 0.704 16.8  0.191 17.0  0.919 25.2 
50 0.719 23.5  0.204 25.2  0.919 39.9 
100 0.732 31.7  0.218 34.8  0.933 46.2 
150 0.734 38.1  0.224 40.8  0.938 66.6 
200 0.748 41.1  0.226 40.9  0.938 80.8 
250 0.747 37.8  0.232 49.4  0.933 83.6 
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Figure 2.7. Redox potentials of 1–3 measured in H2O. The oxidation of 1, 3, and DMPD was 
monitored by cyclic voltammetry. Conditions: [compound] = 1 mM, 1 M NaCl (in ddH2O), various 
scan rates [25 (red), 50, 100, 150, 200, and 250 mV/s (blue)], room temperature, three electrodes 
composed of the glassy carbon working electrode, platinum counter electrode, and Ag/Ag(I) reference 
electrode. 
 
 
Table 2.3. Quantitative data of cyclic voltammograms of 1–3 in H2O. 
 
Scan rate 
(mV/s) 
DMPD 
Epa (V) ipa (A) Epc (V) ipc (A) 
25 0.138 4.19 0.0830 4.16 
50 0.141 8.88 0.0840 8.68 
100 0.139 14.8 0.0820 14.1 
150 0.140 22.9 0.0840 22.5 
200 0.140 31.8 0.0840 26.4 
250 0.141 37.6 0.0860 34.2 
Scan rate 
(mV/s) 
1 
Epa (V) ipa (A) Epc (V) ipc (A) 
25 0.0960 8.91 – – 
50 0.107 12.4 0.0994 1.90  
100 0.111 25.6 0.0987 3.67 
150 0.103 22.7 0.103 5.94 
200 0.106 44.4 0.101 11.3 
250 0.109 58.0  0.100  15.8 
Scan rate 
(mV/s) 
3 
Epa (V) ipa (A) Epc (V) ipc (A) 
25 0.557 10.4 0.491 5.00  
50 0.560 13.8 0.488 6.63 
100 0.560 17.4 0.491 8.11 
150 0.563 19.9 0.490 8.24 
200 0.565 23.5 0.488 12.5 
250 0.567 28.7 0.491 17.2 
 
In addition to the moieties of DMPD and BT, the oxidation of the thiol groups in 1 and 2 was 
monitored by the DTNB assay [DTNB = 5,5’-dithio-bis-(2-nitrobenzoic acid)] with L-cysteine as a 
positive control (Scheme 2.2 and Figure 2.8). A new absorption band at ca. 412 nm was exhibited 
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upon reaction of the thiol groups in 1 and 2 with the disulfide bond in DTNB, indicative of the 
formation of 2-nitro-5-thiobenzoic acid dianion (TNB2-) (Figure 2.8). The different intensity of the 
optical bands of TNB2-, resulted from the interactions of DTNB with compounds, presents that the 
thiol group in 1 is less oxidizable than that in 2. 
 
Scheme 2.2. Reaction scheme of the DTNB assay 
 
 
 
 
Figure 2.8. Oxidation of thiol groups in L-cysteine (L-Cys) and compounds, monitored by the DTNB 
assay. L-Cys was used as a positive control in the DTNB assay. Conditions: [DTNB] = 50 M; 
[compound] = 50 M; buffered solution (pH 8.0); room temperature; incubation for 10 min.  
 
 Based on the redox properties of 1–3, analyzed through CV and the DTNB assay, their oxidation 
was additionally traced for 24 h by UV–Vis (Figure 2.9). The absorption band of 1 decreased at ca. 
254 nm and increased at ca. 300 nm upon incubation, indicative of oxidation producing the 
delocalized electron(s) on the phenyl ring.37,39 Different from 1, the intensity of the optical band of 2 
was slightly reduced at ca. 280 nm, whereas the peak intensity was enhanced in the range of ca. 290 
to 400 nm. The spectral changes of 3 were not detected even for 24 h (Figure 2.9), suggesting that the 
compound was not easily oxidizable under our experimental conditions. Therefore, the moiety of 
DMPD in 1 is suggested to be more associated with ligand oxidation than the BT portion found in 2 
and 3, which is consistent with the results of CV (Figure 2.6). More importantly, the different degree 
of the compounds’ oxidation is demonstrated to be achieved via a minor structural difference (i.e., 
replacement of only one donor atom in the backbone; Figure 2.1c). These distinct redox properties of 
compounds are observed to direct their distinguishable interactions as well as modulating reactivities 
towards metal-free A, metal–A, and free radicals (vide infra). 
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Figure 2.9. Oxidation of 1–3 monitored by UV–Vis. Conditions: [compound] = 50 M; 20 M 
HEPES, pH 7.4, 150 M NaCl; room temperature; incubation for 24 h. 
 
2.2.4. Interactions of 1–3 with Metal-free A 
To verify how the distinct redox properties of 1–3 could influence their reactivities towards A 
aggregation, the interactions of 1–3 with metal-free A species were identified at the molecular level 
employing electrospray ionization mass spectrometry (ESI–MS) and tandem MS (ESI–MS2) (Figure 
2.10). Upon incubation of metal-free A40 with or without the compounds, the +3-charged A40 
monomer ([A40 + 3H]3+) was detected at 1444 m/z in the ESI–MS spectra (red peaks; Figure 2.10a). 
Among our small molecules, 1 was observed to oxidize metal-free A40 showing the peak at 1449 m/z 
corresponding to [A40 + O + 3H]3+ (red asterisk; Figure 2.10a), while such peptide modification was 
not monitored in the case of metal-free A40 treated with both 2 and 3. 
 

 
Figure 2.10. Interactions of 1–3 with metal-free A40, analyzed by ESI–MS and ESI–MS2. (a) The 
+3-charged A40 monomers in the samples incubated with 1–3 in the absence of Cu(II) were detected 
in the ESI–MS spectra. Metal-free A40 is denoted as red peaks. The oxidized ions are indicated by 
the red asterisks. (b) The oxidized amino acid residue of A40 incubated with 1 was identified through 
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ESI–MS2. Conditions: [A40] = 100 M; [compound] = 500 M; incubation for 3 h; 20 mM 
ammonium acetate, pH 7.2; 37 °C; no agitation. All samples were diluted with ddH2O by 10 fold 
before injection to the mass spectrometer. 
 
Furthermore, we determined which amino acid residues of metal-free A40 were plausibly oxidized 
upon treatment of 1 through ESI–MS2 (Figure 2.10b). The ESI–MS2 spectrum of 1-added A40 
displayed that the methionine 35 (M35) residue in A40 was oxidized (e.g., methionine sulfoxide).48,49 
In the previous studies, the oxidation of M35 in A has been suggested to modify A aggregation 
pathways.50,51 Together, among our molecules (1–3), 1 with the lowest Epa value is capable of 
oxidizing metal-free A40, implying that the interactions of compounds with metal-free A40 could be 
linked to their redox properties. 
 
2.2.5. Interactions of 1–3 with Cu(II)–A 
In addition to metal-free A40, the interactions of 1–3 with Cu(II)-treated A40 species were 
investigated (Figure 2.11). Note that compounds’ interactions with Zn(II)–A could not be studied 
since Zn(II)- bound A species were not observed under our MS conditions. Upon incubation of A40 
in the presence of Cu(II), Cu(II)- added A40 (i.e., [A40 + Cu(II) + H]3+) was revealed at 1465 m/z, 
along with metal-free A40 at 1444 m/z (red and light blue peaks; Figure 2.11). Compound 1 with the 
lowest oxidation potential was shown to degrade and oxidize Cu(II)-treated A40 (orange peaks and 
red asterisks, respectively; Figure 2.11). The degraded A40 by 89 Da could be induced by oxidative 
cleavage of the aspartate 1 (D1) residue forming isocyanate.52-54 The D1 residue was reported to be 
preferentially oxidized through alkoxyl radical pathways,52-54 which could impact the structural 
rearrangement of Cu(II) coordination in A. In addition to the degraded A40 (at 1415 m/z), the peak 
at 1409 m/z could be assigned as the degraded A40 with further loss of one water (H2O) molecule. In 
a similar manner, the peaks at 1421 m/z and 1427 m/z (peptide species bound to one and two H2O, 
respectively) might indicate the degradation of A40.  
The oxidation sites in the amino acid sequence of Cu(II)-added A40 induced by 1 were determined 
by ESI–MS2 (Figure 2.11b). Under Cu(II)-present conditions, histidine 13 and 14 (H13 and H14) were 
shown to be oxidized, along with M35, previously reported as the plausibly oxidizable residues in 
A.48,50,51,55,56 Since Cu(II) is known to be bound to H13 and H14 in A,3,5,45 their oxidation (e.g., 2-
oxo histidine)57 upon incubation of A with 1 might explain the low abundance of Cu(II)–A40 in the 
spectra (Figure 2.11b). Additionally, the oxidation of H13, H14, and M35 in A is previously reported 
to alter A aggregation pathways.50,51 
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Figure 2.11. Interactions of 1–3 with Cu(II)-treated A40, analyzed by ESI–MS and ESI–MS2. (a) The 
+3-charged A40 monomers in the samples incubated with 1–3 in the presence of Cu(II) were detected 
in the ESI–MS spectra. Cu(II)–A40 is denoted as light blue peaks, respectively. The oxidized ions are 
indicated by the red asterisks. The number of the asterisks represents the number of the oxygen atoms 
incorporated into A40. The degraded A40 with 89 Da loss (orange peaks) was presented from the 1-
treated samples in the presence of Cu(II). (b) The oxidized amino acid residues of A40 incubated 
with 1 and Cu(II) were identified through ESI–MS2. Conditions: [A40] = 100 M; [CuCl2] = 100 
M; [compound] = 500 M; incubation for 1 h; 20 mM ammonium acetate, pH 7.2; 37 °C; no 
agitation. All samples were diluted with ddH2O by 10 fold before injection to the mass spectrometer. 
 
Compound 2, which possesses the higher oxidation potential than 1 (Figure 2.6), indicated 
different interactions with Cu(II)-treated A40, compared with 1. In detail, 2 significantly reduced the 
intensity of peaks at 1465 m/z corresponding to [A40 + Cu(II) + H]3+, suggesting that the 
coordination of Cu(II) to A40 was modified by incubation with 2 (Figure 2.11). Distinct from 1, 2 
was not able to degrade and oxidize A even in the presence of Cu(II). In order to further analyze the 
interaction of 2 with Cu(II)–A, we additionally employed Cu(II)-treated A42, another isoform of A 
(Figure 2.12).12 When 2 was incubated with Cu(II) and A42, the peak of Cu(II)–A42 disappeared, 
supporting that this molecule might also disrupt Cu(II) binding to A42 (blue peaks; Figure 2.12a). 
Moreover, compound 2 was observed to be transformed to BT58 (153 Da) or the oxidized BT (BTox; 
304 Da) under Cu(II)-present conditions. These transformed compounds from 2, BT and BTox, were 
shown to subsequently form the non-covalent adduct with the A42 dimer at 1868 m/z (green peaks; 
Figure 2.12a). Moving forward, we applied ion mobility mass spectrometry (IM–MS) to monitor the 
effects of 2 on conformation of the A42 dimer (Figure 2.12b). The arrival time distribution (ATD) of 
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the A42 dimer, monitored after addition of 2 into the sample of Cu(II)-treated A42, was enhanced at 
11.57 ms, implying that 2 could trigger the conformational compaction of the dimeric form. Thus, 2 is 
able to specifically interact with Cu(II)-treated A over metal-free A, especially showing the non-
covalent complexation between the compound and the A42 dimer with conformational changes when 
Cu(II) is present. These interactions of 2 with Cu(II)–A42 are exhibited to be related to its modulating 
activity towards the aggregation of Cu(II)–A42 (vide infra).  
 
 
 
Figure 2.12. Interactions of 2 with Cu(II)-treated monitored A42 monitored by ESI–MS and IM–MS. 
(a) The +5-charged Cu(II)-treated A42 dimer in the samples incubated without (left) or with 2 (right). 
The non-covalent complex formation of BT (153 m/z) or BTox (304 m/z) with A42 was detected in the 
ESI–MS spectra (green peak, 1868 m/z). (b) The altered arrival time distributions (ATDs) of Cu(II)–
A42 upon incubation with 2 indicate the conformational change of the peptide. Ions selected for the 
IM–MS analysis are marked with gray and orange circles in the ESI–MS spectra. Conditions: [A42] = 
100 M; [CuCl2] = 100 M; [2] = 500 M; incubation for 1 h; 20 mM ammonium acetate, pH 7.2; 
37 °C; no agitation. All samples were diluted with ddH2O by 10 fold before injection to the mass 
spectrometer. 
  
Lastly, the hardly oxidizable compound 3, relative to 1 and 2, displayed no significant interaction 
with Cu(II)-treated A40. For example, 3 was not able to degrade and oxidize A as well as generate 
non-covalent complexes with peptides (Figure 2.11b). In summary, the easily oxidized compound, 1, 
is observed to considerably interact with both metal-free and Cu(II)-treated A. Compound 2 (with 
the higher Epa value than 1) specifically affects Cu(II) binding to both A40 and A42 and produces a 
non-covalent adduct with the A42 dimer showing structural compaction. The least oxidizable 
compound, 3, among our molecules could not interact with both metal-free A and Cu(II)–A. Taken 
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together, our MS studies support that the interactions between our compounds and metal-free or 
Cu(II)-treated A could be differentiated depending on their redox properties which were rationally 
tuned via a very minor structural variation (Figure 2.1c). 
 
2.2.6. Regulatory Abilities of 1–3 against Metal-free A and Metal–A Aggregation 
To confirm the compounds’ regulatory activities against metal-free A and metal–A, the capability 
of 1–3 to control peptide aggregation with and without metal ions was evaluated. The resultant A 
species upon treatment with compounds were analyzed by gel electrophoresis/Western blotting 
(gel/Western blot; for size distribution) with an anti-A antibody (6E10) and transmission electron 
microscopy (TEM; for morphology). In the inhibition experiments (Figure 2.13), freshly prepared A 
was introduced with our compounds in the absence and presence of metal ions [i.e., Cu(II) and Zn(II)] 
for 24 h. In the disaggregation experiments (Figure 2.14), the compounds were added to preformed 
metal-free or metal-added A aggregates, generated by 24 h incubation, and the resultant samples 
were additionally incubated for 24 h. The larger A aggregates (e.g., fibrils), generated from both 
experiments, are known to limit their penetration through the gel matrix; thus, they are in general 
visualized by TEM.59,60 When A aggregation is varied with the treatment of compounds producing 
small-sized A species, smearing bands in the gel/Western blot are presented.59,60  
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Figure 2.13. Reactivities of 1–3 to inhibit metal-free A and metal–A aggregation. (a) Scheme of the 
inhibition experiments. (b) Analysis of the size distributions of the resultant A40 and A42 species 
from (a) by gel/Western blot using 6E10. (C) [A ± Cu(II) or Zn(II)]; (1) [(C) + 1]; (2) [(C) + 2]; (3) 
[(C) + 3]. Conditions: [A] = 25 M; [CuCl2 or ZnCl2] = 25 M; [compound] = 50 M; pH 6.6 [for 
Cu(II) samples] or pH 7.4 [for metal-free and Zn(II) samples]; 37 °C; constant agitation. (c) TEM 
images of the samples from (b). The inset image represents the minor species. Scale bar = 200 nm. 
 
 
 
 
Figure 2.14. Reactivities of 1–3 against the preformed metal-free and metal-induced A40/A42 
aggregates. (a) Scheme of the disaggregation experiments. (b) Analysis of the size distributions of the 
resultant A40 and A42 species from (a) by gel/Western blot using 6E10. (C) [A ± Cu(II) or Zn(II)]; 
(1) [(C) + 1]; (2) [(C) + 2]; (3) [(C) + 3]. Conditions: [A] = 25 M; [CuCl2 or ZnCl2] = 25 M; 
[compound] = 50 M; pH 6.6 [for Cu(II) samples] or pH 7.4 [for metal-free and Zn(II) samples]; 
37 °C; constant agitation. (c) TEM images of the resultant A40/A42 aggregates from the 24 h 
incubated samples from (b). Scale bar = 200 nm. 
 
When metal-free A40/A42 and metal–A40/A42 were incubated with 1, noticeable smearing 
bands of the resultant A40 and A42 species with lower molecular weights were observed in the 
gel/Western blots (Figure 2.13b). These results suggest that 1 is able to significantly modulate A 
aggregation pathways in the absence and presence of metal ions. In addition, 1 is shown to 
disaggregate preformed metal-free A40/A42 and metal–A40/A42 aggregates or affect their further 
㸰㸳 
 
aggregation (Figure 2.14b). TEM images of the A aggregates formed upon treatment of 1 in both 
inhibition and disaggregation studies were amorphous and smaller sized instead of larger and fibrillar 
aggregates observed from compound-free A samples (Figures 2.13c and 2.14c). 
In the case of 2, this molecule could not regulate metal-free A40 and metal–A40 aggregation in 
both inhibition and disaggregation experiments (Figures 2.13b and 2.14b). Different from A40, 
smearing bands of Cu(II)–A42 aggregates, larger than 140 kDa, were observed upon incubation with 
2, which could indicate its specific reactivity towards the aggregation of Cu(II)–A42 over metal-free 
A42 and Zn(II)–A42 (Figures 2.13b and 2.14b). In accordance with the results of gel/Western blot, 
shorter-sized A aggregates were shown only in the samples containing 2 and Cu(II)-treated A42 in 
both inhibition and disaggregation experiments (Figures 2.13c and 2.14c). Lastly, 3 could not modify 
the aggregation of metal-free A40/A42 and metal–A40/A42 based on the results of gel/Western blot 
(Figures 2.13b and 2.14b). No noticeable morphological changes of 3-added A aggregates, produced 
with and without metal ions, were visualized (Figures 2.13c and 2.14c). 
The reactivities of 1–3 against the aggregation of metal-free A and metal–A are consistent with 
the trend of their Epa values (Figure 2.6) as well as the observation for the interactions with metal-free 
and metal-bound A species (Figures 2.10-2.12). Compound 1 with the lowest Epa value could trigger 
the oxidation of metal-free A (at M35) as well as the degradation (at D1) and oxidation (at H13, H14, 
and M35) of Cu(II)–A. Such interactions could lead to modifying metal-free and metal-induced A 
aggregation by 1. Compound 2 with the higher Epa value than 1 could disrupt the coordination of 
Cu(II) to A and generate a non-covalent complex with the A42 dimer showing structural compaction 
with Cu(II) being present; thus, the molecule could noticeably control Cu(II)–A42 aggregation. In the 
case of 3 with the highest Epa value among our molecules, the compound was not able to interact with 
metal-free A and Cu(II)–A, which could support no reactivities of the molecule towards the 
aggregation of both metal-free A and metal–A. Taken together, the ability of compounds to 
modulate the aggregation of A40 and A42 with or without metal ions is demonstrated to be highly 
relevant to their characteristics, including redox properties and interactions with the targets. 
 
2.2.7. Antioxidant Capabilities of 1–3 against Free Radicals 
To determine if the redox properties of compounds can direct their regulatory activity against free 
radicals, the ability of 1–3 to quench free radicals was evaluated by the Trolox equivalent antioxidant 
capacity (TEAC) assay employing the lysates of Neuro-2a (N2a) neuroblastoma cells (Figure 2.15a). 
The TEAC assay verifies the capability of compounds to scavenge free radicals, such as ABTS+• 
[ABTS = 2,2’-azinobis-(3-ethylbenzothiazoline-6-sulfonic acid)], relative to that of an analog of 
vitamin E, Trolox (6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid).39,61-63 The quenching 
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ability of Trolox against free radicals is well characterized; thus, small molecules with the TEAC 
values higher than 1.0 are regarded as potent antioxidants than Trolox.61 Compound 1 is presented to 
have the TEAC value as 1.6 (± 0.1), suggesting this molecule as a better scavenger against free 
radicals than Trolox (Figure 2.15). Compound 2 also quenches free radicals [the TEAC value as 0.33 
(± 0.04)] but its activity is much lower than 1 and Trolox. As expected, 3 with the highest oxidation 
potential exhibits the lowest TEAC value [0.03 (± 0.01)]. Collectively, the trend of the TEAC values 
of 1–3 is observed to be well matched with the degree of their oxidation (Figures 2.6 and 2.7). 
 
 
 
Figure 2.15. Scavenging capability of 1–3 against free organic radicals in N2a cell lysates, 
determined by the TEAC assay. The TEAC values of compounds are summarized in (b). *n.d., not 
determined. The TEAC values of ethanamine (EA) and ethanethiol (ET) were not able to be obtained 
due to their limited activity. 
 
In order to identify which structural portions contribute to the antioxidant capability of our 
compounds (especially, 1 and 2), we further investigated the ability of structural components of 1–3 
[i.e., DMPD, BT, ethanamine (EA), ethanethiol (ET); Figure 2.15] to scavenge free radicals. The 
TEAC value of DMPD is 1.0 (± 0.03), much higher than that of BT [0.02 (±0.03)], which could 
explain the better antioxidant capability of 1 containing DMPD, compared to 2 and 3 possessing BT. 
In the case of EA and ET, their TEAC values could not be measured due to their limited activity 
against free radicals. In addition to the individual parts, the entire structure of the compounds might 
be shown to be important for their antioxidant capacity (1 versus DMPD; Figure 2.15b). Overall, the 
antioxidant capability of compounds is confirmed to be associated with their chemical structures that 
consequently differentiate their oxidation potentials. 
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Figure 2.16. Toxicity of compounds in SH-SY5Y (5Y) cells. (a) Cell survival of compounds (1–3) in 
the absence of metal ions. (b) Cell survival of compounds (i.e., 1 and 2) in the presence of metal ions. 
(c) Cell survival of compounds (i.e., 1 and 2) in the presence of A40 or A42 and metal ions. 
Conditions: [A] = 10 M, [CuCl2 or ZnCl2] = 5 M, [compound] = 10 M. 

2.3. Conclusions 
Novel small molecules, composed of DMA and bidentate ligands, were newly constructed for 
regulating distinct factors linked to AD pathology to different extents. The development of such 
compounds was achieved via our rational structure-property-directed design principle employing a 
very straightforward structural modification. The distinguishable characteristics of the small 
molecules, including redox properties and interactions with pathological components, were obtained 
through our simple structural variation. The relatively easily oxidizable compound, 1, is demonstrated 
to effectively modify multiple pathogenic factors, i.e., metal-free and metal-bound A as well as free 
radicals. In addition, 2, which is less easily oxidized than 1, presents the specific reactivity towards 
the aggregation of Cu(II)–A42, along with less scavenging ability against free radicals than that of 1. 
The hardly oxidizable compound, 3, could not influence the actions of all pathogenic components, i.e., 
metal-free A, metal–A, and free radicals. Therefore, our studies reveal that a very minor structural 
change could successfully tune their properties (especially, oxidation potentials) as well as regulatory 
reactivities towards distinct pathogenic elements found in AD. 
In order to evaluate biological applications of our small molecules, their cytotoxicity was 
examined employing human neuroblastoma SH-SY5Y cells through the MTT assay [MTT = 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] (Figure 2.16). Compound 1 was observed to 
have no cytotoxicity up to 10 M (cell viability, ca. 100%; Figure 2.16). In the case of 2 and 3, the 
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compounds were less toxic up to 25 M (cell viability, ca. 80-100%) (Figure 2.16). When the cells 
incubated with A and 1 (the compound with regulatory reactivities towards multiple pathological 
factors) in the absence and presence of metal ions, the cell survival was enhanced by ca. 10 to 20% 
(Figure 2.16). To improve the utilization of such molecules in biological systems, further structural 
optimization would be necessary. To conclude, our structure-property-directed design demonstrates 
the feasibility of building up novel structural entities useful for devising chemical tools towards 
modulation of single or multiple pathogenic factor(s) found in AD. 
 
2.4. Experimental Section 
2.4.1. Materials and Methods 
All reagents were purchased from commercial suppliers and used as received unless otherwise noted. 
Cyclic voltammograms were recorded under N2 (g) with a CHI620E model potentiostat (Qrins, Seoul, 
Republic of Korea). A three-electrode setup is composed of an Ag/Ag(I) reference electrode [RE-1B 
Reference electrode [Ag/Ag(I); Qrins], a Pt wire auxiliary electrode (SPTE Platinum electrode; Qrins), 
and a glassy carbon working electrode (Qrins). A40 and A42 (A42 = 
DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA) were purchased from Anaspec 
(Fremont, CA, USA). Trace metal ions were removed from the solutions used in the studies by 
treating the solutions with Chelex overnight (Sigma-Aldrich, St. Louis, MO, USA). Optical spectra 
were recorded using an Agilent 8453 UV–Vis spectrophotometer. Absorbance values for biological 
assays, including the PAMPA–BBB, TEAC, and MTT assays, were measured using a Molecular 
Devices SpectraMax M5e microplate reader (Sunnyvale, CA, USA). TEM images were taken by a 
JEOL JEM-2100 transmission electron microscope [UNIST Central Research Facilities (UCRF), 
Ulsan, Republic of Korea]. ESI–MS and IM–MS analyses were performed using a Waters Synapt G2-
Si quadrupole time-of-flight (Q-Tof) ion mobility mass spectrometer (Waters, Manchester, UK) 
equipped with an ESI source [DGIST Center for Core Research Facilities (CCRF), Daegu, Republic 
of Korea]. 1H and 13C NMR spectra were recorded using a 400 MHz Agilent NMR spectrometer 
(UCRF). The high-resolution mass spectra of compounds were obtained through a Q exactive plus 
orbitrap mass spectrometer (Thermo Fisher Scientific, Carlsbad, CA, USA).  
 
2.4.2. Preparation of 1 
Ethylene sulfide (150 L, 2.5 mmol) was added dropwise into a solution of dimethyl-4-
phenylenediamine (690 mg, 5 mmol) in EtOH (3 mL) and the reaction mixture was heated to 100 °C 
under N2 (g). After 2 h, ethylene sulfide (100 L, 1.7 mmol) was added dropwise. After 1 h, the 
solvent was removed under vacuum. The residue was dissolved in water and extracted with ethyl 
acetate (EtOAc; 3x). The combined organic layer was dried over anhydrous magnesium sulfate 
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(MgSO4) and concentrated under the vacuum. The crude compound was purified by column 
chromatography (SiO2; EtOAc:hexanes = 1:3) yielding a product (white oil; 140 mg, 0.71 mmol, 
29%). 1H NMR [400 MHz, CD2Cl2, 	 (ppm)]: 6.71 (2H, d, J = 8.8 Hz), 6.61 (2H, d, J = 8.8 Hz), 3.57 
(1H, br), 3.28 (2H, t, J = 6.4 Hz), 2.81, (6H, s), 2.73 (2H, m), 1.48 (1H, m). 13C NMR [100 MHz, 
CD2Cl2, 	 (ppm)]: 144.9, 140.1, 115.8, 115.0, 48.2, 42.2, 24.9. HRMS (m/z): [M + H]+ Calcd. for 
C10H16N2S, 197.1107; found, 197.1102. 
 
2.4.3. Preparation of 2 
4-Iodoaniline (660 mg, 3.0 mmol), 2-mercaptoethanol (0.42 mL, 6.0 mmol), copper sulfate 
pentahydrate (CuSO4∙5H2O; 38 mg, 0.15 mmol), and KOH (840 mg, 15 mmol) were added into a test 
tube containing DMSO/H2O (2 mL/0.2 mL) with a magnetic stir bar. After flushing with Ar (g), the 
mixture was stirred in a preheated oil bath at 90 °C for 20 h and then cooled to room temperature. The 
reaction was quenched with water and extracted with EtOAc (4x). The organic layer was washed with 
water (1x) and brine (1x) and then concentrated under vacuum. The crude product was purified by 
column chromatography (SiO2; EtOAc:hexanes = 1:1) yielding a primary amine product (yellow oil; 
360 mg, 2.1 mmol, 70%).  
A mixture of 3 M sulfuric acid (H2SO4; 1.2 mL, 3.4 mmol) and formaldehyde (aq, 37% w/w, 0.64 
mL, 8.4 mmol) was cooled to 0 °C. A slurry of 2-((4-aminophenyl)thio)ethanol (360 mg, 2.1 mmol) 
and sodium borohydride (NaBH4; 480 mg, 13 mmol) in tetrahydrofuran (THF; 5 mL) was added 
dropwise into the solution. After stirring the solution for 1 h, the reaction mixture was basified with 1 
N sodium hydroxide (NaOH; aq) and then extracted with EtOAc (3x). The combined organic phase 
was washed with brine (1x), dried over anhydrous MgSO4, and concentrated under vacuum. The 
crude compound was purified by column chromatography (SiO2; EtOAc:hexanes = 1:1) yielding a 
tertiary amine product (white solid; 330 mg, 1.7 mmol, 79%). 
A solution of 2-((4-(dimethylamino)phenyl)thio)ethanol (340 mg, 1.7 mmol) and thiourea (140 mg, 
1.9 mmol) in HCl (aq) (0.6 mL) was stirred at 100 °C for 6 h. The reaction mixture was cooled to 
50 °C. A solution of NaOH (aq; 20% w/w, 0.39 mL) was slowly added to the reaction solution, and 
then white solid precipitates were obtained. The reaction mixture was stirred at 70 °C for 1 h until the 
white precipitates disappeared. The reaction was quenched with water and extracted with EtOAc (3x). 
The organic layer was washed with brine (1x), dried over anhydrous MgSO4, and concentrated under 
vacuum. The crude product was purified by column chromatography (SiO2; EtOAc:hexanes = 1:2) 
yielding a thiol product (140 mg, 0.65 mmol, 12%). 1H NMR [400 MHz, CD2Cl2 , 	 (ppm)]: 7.31 (2H, 
d, J = 8.1 Hz), 6.65 (2H, d, J = 8.8 Hz), 2.94 (6H, s), 2.91 (2H, m) 2.62 (2H, m), 1.72 (1H, t, J = 8.1 
Hz). 13C NMR [100 MHz, CD2Cl2, 	 (ppm)]: 150.8, 135.0, 119.3, 113.1, 41.1, 40.5, 24.7. HRMS 
(m/z): [M + H]+ Calcd. for C10H15NS2, 214.0719; found, 214.0714.  
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2.4.4. Preparation of 3 
4-Iodo-N,N-dimethylaniline (490 mg, 2.0 mmol), 2-(Boc-amino)ethanethiol (680 L, 4.0 mmol), 
copper acetate dihydrate [Cu(OAc)2∙2H2O; 40 mg, 0.2 mmol], and potassium carbonate (K2CO3; 1.1 g, 
8.0 mmol) were added into a test tube containing DMSO/H2O (3 mL/1 mL) with a magnetic stir bar. 
After flushing with Ar (g), the mixture was stirred in a preheated oil bath at 90 °C for 24 h. After 
cooling the solution to room temperature, the reaction was quenched with EtOAc. The reaction 
solution was washed with water (3x) and brine (1x). The organic layer was dried over anhydrous 
MgSO4 and concentrated under vacuum. The crude product was purified by column chromatography 
(SiO2; EtOAc:hexanes = 1:10) yielding a product (white solid; 210 mg, 0.71 mmol, 34%).  
tert-Butyl 2-(4-(dimethylamino)phenylthio)ethylcarbamate (400 mg, 1.4 mmol) was added into the 
solution of HCl/dioxane (4.0 M, 10 mL) at 0 °C under Ar (g). The reaction mixture was stirred at 
room temperature for 24 h. The solvent was removed under vacuum and the residue was washed with 
diethyl ether (Et2O). The sticky compound was basified with 1 N NaOH (aq) and extracted with 
EtOAc (3x). The combined organic layer was washed with brine (1x), dried over anhydrous MgSO4, 
and concentrated under vacuum. The crude compound was purified by column chromatography (SiO2; 
CH2Cl2:CH3OH = 7:1). A product (white powder; 50 mg, 0.25 mmol, 18%) was obtained by addition 
of Et2O to the yellow liquid product. 1H NMR [400 MHz, CD3OD, 	 (ppm)]: 7.35 (2H, m), 6.72 (2H, 
d, J = 8.8 Hz), 2.94 (10H, m), 1.90 (2H, s). 13C NMR [100 MHz, CD3OD, 	 (ppm)]: 152.2, 136.0, 
119.2, 114.2, 40.6. 39.8, 35.5. HRMS (m/z): [M + H]+ Calcd. for C10H16N2S, 197.1107; found, 
197.1103. 
 
2.4.5. Metal Binding Studies  
The interactions of compounds with metal ions [Cu(II) and Zn(II)] were determined using UV–visible 
spectroscopy (UV–Vis). The solutions of compounds (50 M; 1% v/v DMSO) were prepared in EtOH 
for [Cu(II) samples] or buffer [20 M HEPES, pH 7.4, 150 M NaCl; for Zn(II) samples). Various 
concentrations of CuCl2 or Zn(NO3)2 (25, 50, 100, and 250 M) were titrated to the solutions of the 
compound. The UV–Vis spectra were recorded after 10 min incubation for every titration at room 
temperature. 
 
2.4.6. Cyclic Voltammetry (CV) 
Cyclic voltammograms were recorded under N2 (g) with a CHI620E model potentiostat (Qrins) with 
three electrodes composed of an Ag/AgCl reference electrode [RE-1B Reference electrode (Ag/AgCl); 
Qrins], a Pt wire auxiliary electrode (SPTE Platinum electrode; Qrins), and a glassy carbon working 
electrode (Qrins). Electrochemical analyses of compounds (dissolved in DMSO; final concentration, 1 
mM) were recorded in 0.1 M tetra-N-butylammonium perchlorate (in DMSO) and 1 M NaCl (in 
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ddH2O; 1% v/v DMSO) at various scan rates (25, 50, 100, 150, 200, and 250 mV/s) at room 
temperature.  
 
2.4.7. DTNB Assay 
The oxidation of a thiol group in our compounds was evaluated through the DTNB assay [DTNB = 
5,5’-dithio-bis-(2-nitrobenzoic acid)]. The solutions of DTNB (50 M) were prepared in 0.1 M 
sodium phosphate buffer, pH 8.0, 1 mM EDTA, followed by treatment of L-cysteine, as a positive 
control, and small molecules (50 M; 1% v/v DMSO). The DTNB molecule can react with the thiol 
groups in small molecules, yielding a product containing a newly formed disulfide bond and a yellow-
colored compound, 2-nitro-5-thiobenzoic acid dianion (TNB2-).64 After 15 min incubation at room 
temperature, the absorbance of TNB2- at 412 nm was measured. 
 
2.4.8. Stability of Compounds 
The oxidation of compounds was traced by UV–Vis. The solutions of compounds (50 M; 1% v/v 
DMSO) were prepared in buffer (20 M HEPES, pH 7.4, 150 M NaCl). The compound was 
incubated for 24 h at room temperature without agitation.  
 
2.4.9. TEAC Assay 
The assay employing Neuro2a (N2a) cell lysates was conducted following the previously reported 
methods.34,63 Cell lysates were prepared following a previously reported procedure with 
modifications.65 N2a cells were seeded in a six-well plate and grown to approximately 80-90% 
confluence. Cells were washed once with cold phosphate buffered saline (PBS, pH 7.4, GIBCO, 
Grand Island, NY, USA) and harvested by gently pipetting off adherent cells with cold PBS. The cell 
pellet was generated by centrifugation (2,000 g for 10 min at 4 °C) and sonicated on ice (5 s pulses, 
3x with 20 s intervals between each pulse) in 2 mL of cold buffer (5 mM potassium phosphate, pH 7.4, 
containing 0.9% NaCl and 0.1% glucose). The cell lysates were centrifuged at 5,000 g for 10 min at 
4 °C. The supernatant was removed and stored on ice until use. To prepare the standard and samples 
in 96 well plates, 10 L of the supernatant of cell lysates was delivered followed by the addition of 
compound (10 L), metmyoglobin (55 M, 10 L), 2,2’-azino-bis(3-ethylbenzothiazoline-6-
sulphonic acid) (ABTS; 220 M, 150 L), and H2O2 (412 M, 40 L) in order. The final 
concentrations (2.14, 4.28. 6.43, 8.57, 10.7, and 15.7 M) of compounds and Trolox were used. After 
5 min incubation at room temperature, the absorbance at 750 nm was recorded. The percent inhibition 
was calculated according to the measured absorbance [% inhibition = 100 ൈ (A0 – A)/A0, where A 
and A0 are the absorbance of the supernatant of cell lysates with and without compound treatment, 
respectively] and was plotted as a function of compound concentration. The TEAC values of 
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compounds for each time point were calculated as a ratio of the slope of the compound to that of 
Trolox. The measurements were conducted in triplicate. 
 
2.4.10. A Aggregation Experiments 
A40 or A42 was dissolved in ammonium hydroxide [NH4OH (aq); 1% v/v]. The resulting solution 
was aliquoted, lyophilized overnight, and stored at –80 °C. A stock solution of A was then prepared 
by dissolving the lyophilized peptide using NH4OH (1% v/v, 10 L) and diluting with ddH2O. All A 
samples were prepared by following the previously reported procedures.34,37,66,67 The concentration of 
the peptide solution was determined by measuring the absorbance of the solution at 280 nm (
 = 1,450 
M–1cm–1 for A40; 
 = 1,490 M–1cm–1 for A42). The peptide stock solution was diluted to a final 
concentration of 25 M in the Chelex-treated buffer [20 M HEPES, pH 6.6 [for Cu(II) samples] and 
pH 7.4 [for metal-free and Zn(II) samples], 150 M NaCl]. For inhibition studies, compounds (final 
concentration, 50 M; 1% v/v DMSO) were added to the samples of A (25 M) in the absence and 
presence of a metal chloride salt (CuCl2 or ZnCl2; 25 M) followed by incubation at 37 °C with 
constant agitation for 24 h. For disaggregation studies, A (25 M) was incubated with and without a 
metal chloride salt (CuCl2 or ZnCl2; 25 M) for 24 h at 37 °C with constant agitation to generate 
preformed A aggregates. The resulting peptide aggregates were then treated with compounds (50 M) 
and incubated with constant agitation for an additional 24 h. 
 
2.4.11. Gel Electrophoresis with Western Blotting (Gel/Western Blot) 
The A resultant species from in vitro experiments were analyzed through gel electrophoresis with 
Western blotting (gel/Western blot) using an anti-A antibody (6E10).34,37,66,67 The samples (10 L) 
were separated on a 10-20% Tris-tricine gel (Thermo Fisher Scientific). Following separation, the 
proteins were transferred onto nitrocellulose membranes and blocked with bovine serum albumin 
(BSA, 3% w/v, Sigma-Aldrich) in Tris-buffered saline (TBS) containing 0.1% Tween-20 (TBS-T) for 
2 h (at room temperature) or overnight (at 4 °C). The membranes were incubated with the anti-A 
antibody (6E10) (1:2,000, Covance, Princeton, NJ, USA) in a solution of 2% BSA (w/v in TBS-T) for 
4 h (at room temperature) or overnight (at 4 °C). After washing with TBS-T (3x, 10 min), a 
horseradish peroxidase-conjugated goat anti-mouse secondary antibody (1:5,000 in 2% w/v BSA in 
TBS-T; Cayman Chemical Company) was added for 1.5 h at room temperature. A homemade ECL 
kit63,68,69 was used to visualize gel/Western blot data on a ChemiDoc MP Imaging System (Bio-Rad, 
Hercules, CA, USA). 
 
2.4.12. Transmission Electron Microscopy (TEM) 
Samples for TEM were prepared according to previously reported methods.34,37,63,66-68 Glow-
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discharged grids (Formvar/Carbon 300-mesh, Electron Microscopy Sciences, Hatfield, PA, USA) 
were treated with A samples (25 M, 5 L) for 2 min at room temperature. Excess sample was 
removed using filter paper followed by washing twice with ddH2O. Each grid, incubated with uranyl 
acetate (1%, ddH2O, 5 L) for 1 min, was blotted off and dried for 15 min at room temperature. 
Images for each sample were taken on a JEOL JEM-2100 transmission electron microscope (200 kV; 
25,000x magnification; UCRF). 
 
2.4.13. MTT Assay 
The SH-SY5Y (5Y) cell line was purchased from the American Type Culture Collection (ATCC, 
Manassas, VA, USA). The cell line was maintained in media containing 50% minimum essential 
medium (MEM) and 50% F12 (GIBCO) and supplemented with 10% fetal bovine serum (Sigma-
Aldrich), 100 U/mL penicillin, and 100 mg/mL streptomycin (GIBCO). Cells were grown and 
maintained at 37 °C in a humidified atmosphere with 5% CO2. The cells used for our studies did not 
indicate mycoplasma contamination. Cell viability upon treatment with compounds was determined 
by the MTT assay [MTT = 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide]. Cells were 
seeded in a 96 well plate (15,000 cells in 100 L per well) and treated with A (10 M) with or 
without CuCl2 or ZnCl2 (5 M), followed by addition of compounds (10 M, 1% v/v DMSO). After 
24 h incubation, MTT [25 L of 5 mg/mL in PBS (pH 7.4, GIBCO)] was added to each well, and the 
plate was incubated for 4 h at 37 °C. Formazan produced by cells was solubilized using an acidic 
solution of DMF (pH 4.5, 50% v/v, aq) and sodium dodecyl sulfate (SDS; 20% w/v) overnight at 
room temperature in the dark. The absorbance was measured at 600 nm by the microplate reader. Cell 
viability was calculated relative to cells containing an equivalent amount of DMSO.  
 
2.4.14. Electrospray Ionization Ion Mobility Mass Spectrometry (ESI–IM–MS) 
The experiments were performed according to previously reported methods.63,68,70 A40 and A42 (100 
M) were incubated with compounds (500 M; 1% v/v DMSO) and/or CuCl2 (100 M) in 20 mM 
ammonium acetate (pH 7.2) at 37 °C without agitation. Incubated samples were diluted by 10 fold 
with water and then injected into the mass spectrometer. A Waters Synapt G2-Si quadrupole time-of-
flight (Q-Tof) ion mobility mass spectrometer (Waters) equipped with ESI source (CCRF) was used 
for the experiments. The capillary voltage, sampling cone voltage, and source temperature were set to 
2.8 kV, 70 V, and 40 °C, respectively. The backing pressure was adjusted to 2.7 mbar. Ion mobility 
wave height and velocity were adjusted to 10 V and 300 m/s, respectively, and gas flow for the helium 
and ion mobility cell was set to 120 and 30 mL/min, respectively. Tandem MS (ESI–MS2) analyses 
were additionally performed on the singly oxidized A and complexes of A with compounds. The 
ESI parameters and experimental conditions were the same as above. Collision-induced dissociation 
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(CID) was conducted by applying the collision energy in the trap and adjusting the low mass (LM) 
resolution to 10 or 15 depending on the samples. More than 200 spectra were obtained for each 
sample and were averaged for the analyses. To estimate the collision cross section (CCS) values of 
IM–MS data, the calibration was also carried out base on the previously reported methods.71 
 
2.4.15. Parallel Artificial Membrane Permeability Assay Adapted for the Blood-brain Barrier 
(PAMPA–BBB)  
PAMPA–BBB experiments were conducted using the PAMPA Explorer kit (pION Inc., Billerica, MA, 
USA) using previously reported protocols.2,5,6 The compounds (25 M, 200 L) in Prisma HT buffer 
(pH 7.4, pION) were added to the wells of a donor plate (number of replicates = 12). The 
polyvinylidene fluoride (PVDF, 0.45 M) filter membrane on the acceptor plate was coated with 
BBB-1 lipid formulation (5 L, pION). The acceptor plate was then placed on the top of the donor 
plate. Brain sink buffer (BSB, 200 L, pION) was added to each well of the acceptor plate and was 
incubated for 4 h at room temperature without agitation. UV–Vis spectra of the solutions in the 
reference, acceptor, and donor plates were measured using the microplate reader. The PAMPA 
Explorer software v. 3.5 (pION) was used to calculate the –logPe values for compounds. 
CNSേdesignations were assigned by comparison with compounds that were identified in previous 
reports.72,73 
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Chapter 3. 
 
Detection of Metal Ions in Living Cells by Fluorescence-based Chemosensors  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The results presented in this chapter were published; (1) Jo, T. G.; Bok, K. H.; Han, J.; Lim, M. H.; 
Kim, C. Dyes Pigm. 2017, 139, 136–147; (2) Jeong, H. Y.; Lee, S. Y.; Han, J.; Lim, M. H.; Kim, C. 
Tetrahedron 2017, 73, 2690–2697; (3) Jo, T. G.; Jung, J. M.; Han, J.; Lim, M. H.; Kim, C. RSC Adv. 
2017, 7, 28723–28732. I conducted the imaging experiments in order to monitor fluorescent responses 
of chemosensors for metal ions in living cells.  
㸱㸷 
 
3.1. Introduction 
Dyshomeostasis of transition metal ions has been suggested to be involved in the pathogenesis of 
neurodegenerative diseases including Alzheimer’s disease (AD) and Parkinson’s disease (PD).1,2 
Particularly, aluminum, the third most prevalent metallic elements in the earth, can be accumulated in 
the regions of the brain, i.e., the cortex and hippocampus, both of which are notably vulnerable at the 
early stage of AD.1,2 Recent studies have revealed that a trace amount of Al(III), transported to the 
brain via blood-brain barrier (BBB), can either intrude metal-mediated signaling pathways [e.g., Ca(II) 
exchange] or replace essential biometals in transporters (e.g., iron carrier transferrin), which induces 
neurotoxicity.3,4 In addition, Al(III) can interfere the activities of iron-sulfur clusters in mitochondrial 
respiratory systems, disrupting the energy production.5,6 Moreover, Al(III) has been reported to 
directly bind A and stabilize structured oligomers.5,6 In order to quantify the concentration of Al(III) 
and monitor its compartmentalization in the brain, various chemosensors able to specifically detect 
this metal ion would be valuable.2,7,8 In this Chapter, we described three chemical tools capable of 
targeting Al(III) in living cells. 
 
3.2. Results and Discussions 
3.2.1. Fluorescent Responses of AIC-Jul to Al(III) in Living Cells 
Scheme 3.1. Proposed structure of the AIC-Jul–Al(III) complex. 
 
 
 
AIC-Jul was rationally designed through the incorporation of imidazole and julolidine (Scheme 3.1).9 
This molecule functions as a turn-on and turn-off fluorescent sensors against Al(III) and 
pyrophosphate (P2O74-, PPi), the product of during hydrolysis of adenosine triphosphate (ATP), 
respectively. Upon incubation of AIC-Jul (20 M, DMSO 1%, v/v) with 5 and 10 equiv of Al(III) for 
10 min, significant fluorescent responses were monitored employing the green fluorescence protein 
(GFP) channel [excitation 470 (± 11) nm; emission 510 (± 21) nm; Figure 3.1a]. Furthermore, the 
AIC-Jul–Al(III) complex was shown to specifically detect PPi among various anions (e.g., Cl-, F-, N3-, 
and NO3-) in the cellular environment. When PPi was treated to cells, pre-incubated with AIC-Jul and 
Al(III), the Al(III)–PPi complex was subsequently formed, indicative of detaching Al(III) from the 
complex. The quenching process achieved via complexation of Al(III)–PPi was monitored using the 
GFP channel (Figure 3.1b). Our experiments demonstrate the potential of AIC-Jul as a sensor for 
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both AI(III) and PPi in living cells.  
 
 
 
Figure 3.1. Fluorescent responses of AIC-Jul to Al(III) in HeLa cells in the absence and presence of 
PPi. (a) Cells were pre-incubated with AIC-Jul for 10 min prior to addition of various concentrations 
of Al(III). (b) Cells incubated with AIC-Jul (for 5 min) followed by addition of Al(III) for 10 min 
were treated with various concentrations of PPi. Conditions: [AIC-Jul] = 20 M; [Al(III)] = 0, 100, 
and 200 M; [PPi] = 0, 100, and 200 M; 37 °C; 5% CO2. The scale bar is 50 m. 
 
3.2.2. Fluorescent Responses of TP-DAS to Al(III) in Living Cells 
Scheme 3.2. Proposed structure of the TP-DAS–Al(III) complex. 
 
 
 
TP-DAS was newly designed by introduction of diethylaminophenol and thiophene into a framework 
(Scheme 3.2).10 Based on competition experiments, Co(II), Ni(II), and Zn(II) could not interfere the 
interactions between TP-DAS and Al(III), while Cu(II) and Fe(II/III) were shown to intrinsically 
quench the fluorescent responses from the TP-DAS–Al(III) complex. Our compound (5 M, DMSO 
1%, v/v) was incubated with Al(III) in HeLa cells for 10 min at various concentrations (Figure 3.2). 
The fluorescent responses of TP-DAS as a function of the concentration of Al(III) were gradually 
enhanced, monitored at the channel of 4’,6-diamidino-2-phenylindole (DAPI) channel [excitation 357 
(± 22) nm; emission 447 (± 30) nm]. Our experimental results reveal that TP-DAS could be a detector 
for Al(III) in biological systems.  
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Figure 3.2. Fluorescent responses of TP-DAS to Al(III) in HeLa cells. Cells were pre-incubated with 
TP-DAS for 10 min prior to addition of various concentrations of Al(III). Conditions: [TP-DAS] = 5 
M; [Al(III)] = 0, 100, 200, and 300 M; 37 °C; 5% CO2. The scale bar is 50 m. 
 
3.2.3. Fluorescent Responses of Sul-Nap to Al(III) in Living Cells 
Scheme 3.3. Proposed structure of the Sul-Nap–Al(III) complex. 
 
 
 
Sul-Nap was rationally designed by integrating a water-soluble sulfonic acid group to the naphthol 
moiety, a widely utilized fluorophore (Scheme 3.3).11 Sul-Nap was presented to selectively recognize 
Al(III) in a 1:1 ratio, followed by a significant change in fluorescence emission in aqueous media. In 
order to examine the potentials of Sul-Nap to be used for sensing Al(III) in biological systems, 
fluorescence imaging experiments were performed (Figure 3.3). HeLa cells were incubated with Sul-
Nap (20 M, DMSO 1%, v/v) for 10 min, prior to treatment of 5 equiv of Al(III) for additional 10 
min. The fluorescence responses of Sul-Nap in the presence of Al(III) were detected at the GFP 
channel [excitation 470 (± 11) nm; emission 510 (± 21) nm]. Note that due to the poor cell 
permeability of the molecule, the concentration-dependent fluorescent responses of Sul-Nap to Al(III) 
could not be monitored (Figure 3.3). 
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Figure 3.3. Fluorescent responses of Sul-Nap in HeLa cells in the (a) absence and (b) presence of 
Al(III). Cells were pre-incubated with Sul-Nap for 10 min prior to addition of Al(III). Conditions: 
[Sul-Nap] = 20 M; [Al(III)] = 100 M; 37 C; 5% CO2. Scale bar = 50 m. 
 
3.3. Conclusions 
Impaired homeostasis of metal ions is found in the AD-affected brain.1,2 In the recent studies, Al(III) 
has been suggested as an additional risk factor in AD, which can facilitate A aggregation and 
interfere the activities of metalloenzymes.3,4 In order to gain a better understanding of Al(III) in AD, 
the design of small molecules able to trace this metal ion would be desirable. In this Chapter, we 
developed three chemical probes, AIC-Jul, TP-DAS, and Sul-Nap, able to detect Al(III) based on 
fluorescence in living cells. In the future, we will further optimize the structures of the molecules in 
order to improve their metal specificity and cytotoxicity. 
 
3.4. Experimental Sections  
3.4.1. Imaging Experiments in Living Cells 
HeLa cells (ATCC, Manassas, USA) were maintained in media containingDulbecco modified eagle 
medium (DMEM), 10% fetal bovine serum (FBS, GIBCO, Grand Island, NY, USA), 100 U/mL 
penicillin (GIBCO), and 100 mg/mL streptomycin (GIBCO). The cells were grown in a humidified 
atmosphere with 5% CO2 at 37 °C. Cells were seeded onto 6 well plate (SPL Life Sciences Co., Ltd., 
South Korea) at a density of 150,000 cells per 1 mL and then incubated at 37 °C for 16 h. For imaging 
experiments, cells were first treated with compound [dissolved in DMSO; 1% v/v final DMSO 
concentration; 5 M (for TP-DAS) or 20 M (for AIC-Jul and Sul-Nap); at room temperature]. After 
10 min, aluminum nitrate (dissolved in water; 1% v/v final concentration; 0-300 M) is introduced to 
cells for 10 min.In case of fluorescence quenching experiments for AIC-Jul, cells were first treated 
with the compound (dissolved in DMSO; 1 % v/v final DMSO concentration; 20 M; at room 
temperature). After 5 min, aluminum nitrite (dissolved in water; 200 M; 1% v/v) was incubated with 
cells 10 min. Various concentrations of PPi (dissolved in bis-tris buffer; 1% v/v) were introduced to 
cells for 5 min and the cells were washed with 3 mL of bis-tris buffer three times. Imaging 
experiments were performed with an EVOS FL fluorescence microscope (Life Technologies) using a 
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DAPI light cube [for TP-DAS; excitation 357 (± 22) nm; emission 447 (± 30) nm] or GFP light cube 
[for AIC-Jul and Sul-Nap; excitation 470 (± 11) nm; emission 510 (± 21) nm]. 
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